Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matias Viitala

Showing results (1-10 of 20) with videos related to

Pageof 2
Sort By:
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 11, 2023
Exposure to systemic antibiotics in outpatient care and the risk of multiple sclerosisJussi Ot Sipilä, Matias Viitala, Arno Hänninen, et al.
International Journal of MS Care|October 10, 2024
MyMS: An Interface for Patient-Reported Outcomes for Finnish Individuals With Multiple SclerosisPäivi Hämäläinen, Matias Viitala, Hanna Kuusisto, et al.
Journal of Neurology|May 2, 2025
Mortality and causes of death for people with multiple sclerosis: a Finnish nationwide register studyKatariina Kuutti, Sini M Laakso, Matias Viitala, et al.
Multiple Sclerosis and Related Disorders|July 4, 2020
Trends and characteristics of infection-related hospital admissions in multiple sclerosis patients in Southwest Finland in 2009-2018Anna-Leena Pirttisalo, Jussi O T Sipilä, Matias Viitala, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|July 1, 2026
Cancer risk and mortality in patients with multiple sclerosis in Finland: a retrospective population-based cohort studyAnna Maunula, Sini M Laakso, Matias Viitala, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|March 18, 2025
Incidence and prevalence of multiple sclerosis during eras of evolving diagnostic criteria-a nationwide population-based registry study over five decadesAnna Maunula, Sini M Laakso, Matias Viitala, et al.
European Journal of Neurology|May 16, 2026
Comparative Effectiveness and Safety of Rituximab Versus Ocrelizumab in Relapsing-Remitting Multiple Sclerosis: A Finnish Population-Based Matched Cohort StudyMaiju Savolainen, Merja Soilu-Hänninen, Henriikka Nurmi, et al.
Multiple Sclerosis and Related Disorders|April 28, 2022
Finnish multiple sclerosis patients treated with cladribine tablets: a nationwide registry studyIlkka Rauma, Matias Viitala, Hanna Kuusisto, et al.
Frontiers in Neurology|May 28, 2019
Thalamic Atrophy Without Whole Brain Atrophy Is Associated With Absence of 2-Year NEDA in Multiple SclerosisKatariina Hänninen, Matias Viitala, Teemu Paavilainen, et al.
Frontiers in Neurology|August 8, 2020
Thalamic Atrophy Predicts 5-Year Disability Progression in Multiple SclerosisKatariina Hänninen, Matias Viitala, Teemu Paavilainen, et al.
Pageof 2

Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 11, 2023
Exposure to systemic antibiotics in outpatient care and the risk of multiple sclerosisJussi Ot Sipilä, Matias Viitala, Arno Hänninen, et al.
International Journal of MS Care|October 10, 2024
MyMS: An Interface for Patient-Reported Outcomes for Finnish Individuals With Multiple SclerosisPäivi Hämäläinen, Matias Viitala, Hanna Kuusisto, et al.
Journal of Neurology|May 2, 2025
Mortality and causes of death for people with multiple sclerosis: a Finnish nationwide register studyKatariina Kuutti, Sini M Laakso, Matias Viitala, et al.
Multiple Sclerosis and Related Disorders|July 4, 2020
Trends and characteristics of infection-related hospital admissions in multiple sclerosis patients in Southwest Finland in 2009-2018Anna-Leena Pirttisalo, Jussi O T Sipilä, Matias Viitala, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|July 1, 2026
Cancer risk and mortality in patients with multiple sclerosis in Finland: a retrospective population-based cohort studyAnna Maunula, Sini M Laakso, Matias Viitala, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|March 18, 2025
Incidence and prevalence of multiple sclerosis during eras of evolving diagnostic criteria-a nationwide population-based registry study over five decadesAnna Maunula, Sini M Laakso, Matias Viitala, et al.
European Journal of Neurology|May 16, 2026
Comparative Effectiveness and Safety of Rituximab Versus Ocrelizumab in Relapsing-Remitting Multiple Sclerosis: A Finnish Population-Based Matched Cohort StudyMaiju Savolainen, Merja Soilu-Hänninen, Henriikka Nurmi, et al.
Multiple Sclerosis and Related Disorders|April 28, 2022
Finnish multiple sclerosis patients treated with cladribine tablets: a nationwide registry studyIlkka Rauma, Matias Viitala, Hanna Kuusisto, et al.
Frontiers in Neurology|May 28, 2019
Thalamic Atrophy Without Whole Brain Atrophy Is Associated With Absence of 2-Year NEDA in Multiple SclerosisKatariina Hänninen, Matias Viitala, Teemu Paavilainen, et al.
Frontiers in Neurology|August 8, 2020
Thalamic Atrophy Predicts 5-Year Disability Progression in Multiple SclerosisKatariina Hänninen, Matias Viitala, Teemu Paavilainen, et al.
Pageof 2